HEALTH

Eli Lilly Agrees to Payments to Settle Dispute: South San Francisco-based Genentech Inc. and Indianapolis-based Eli Lilly & Co. have exchanged numerous patent-infringement complaints over the manufacture and development of growth hormones since 1987. Lilly’s Humatrope competes with Genentech’s Protropin; both are prescribed to spur growth in short children. Lilly agreed to pay Genentech $145 million and future royalties to settle the matter. The companies have granted each other immunity from future suits over the drugs, which are genetically engineered copies of natural proteins, and over the manufacturing processes.